Drug reference

Liraglutide

GLP-1 Receptor Agonist · Antidiabetic, Weight management

Also known as SAXENDA

GLP-1 Receptor AgonistAntidiabetic, Weight management

CDSCO approvedSchedule H

EXCRETION

—

not curated

INTERACTIONS

2 major

SEVERE in our sources

PREGNANCY

Use with caution.

FDA category + note

Top interactionssee all 4 →

BexaroteneSevereDatabaseDDInter
GatifloxacinSevereDatabaseDDInter

Mechanism

Liraglutide binds to, and activates, the GLP1 (glucagon-like peptide-1) receptor to increase insulin secretion, suppresses glucagon secretion, and slows gastric emptying.

Indications

Type 2 diabetes (in combination therapy when other treatment options have failed)Type 2 diabetes with established cardiovascular disease (for cardiovascular benefit)Adjunct in weight management (in conjunction with dietary measures and increased physical activity in individuals with a body mass index (BMI) of 30 kg/m2 or mor)Mitigate antipsychotic-induced weight gainImproved glycemic control in type 2 diabetesWeight loss in obese nondiabetic subjects (at higher doses)Added to oral agents or basal insulin for type 2 diabetestype 2 diabetes mellitus (alone or added to oral metformin ± SU or pioglitazone)antiobesity drug (being evaluated for nondiabetics)

Dosing

Adult: l INDICATIONS AND DOSE Adjunct in obesity (in conjunction with dietary measures and increased physical activity in individuals with a body mass index (BMI) of 30 kg/m2 or more or in individuals with a BMI of 27 kg/m2 or more in the presence of one or more weight related co-morbidity) ▶ BY MOUTH Adult 18–75 years: Initially 1 tablet daily for 7 days, then increased to 1 tablet twice daily for 7 day…